Liquidia Corporation $LQDA Position Lifted by Diametric Capital LP

Diametric Capital LP grew its stake in shares of Liquidia Corporation (NASDAQ:LQDA) by 72.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,601 shares of the company’s stock after acquiring an additional 62,443 shares during the period. Liquidia comprises approximately 1.0% of Diametric Capital LP’s holdings, making the stock its 22nd biggest position. Diametric Capital LP’s holdings in Liquidia were worth $1,852,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of LQDA. Steward Partners Investment Advisory LLC lifted its position in shares of Liquidia by 24.0% during the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock worth $77,000 after purchasing an additional 1,200 shares during the last quarter. Quarry LP bought a new stake in Liquidia in the first quarter valued at about $79,000. Blueshift Asset Management LLC acquired a new stake in Liquidia during the second quarter valued at approximately $127,000. Corsair Capital Management L.P. acquired a new stake in Liquidia during the first quarter valued at approximately $148,000. Finally, Aigen Investment Management LP bought a new position in Liquidia during the 1st quarter worth approximately $151,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $33.92 on Friday. Liquidia Corporation has a 1-year low of $10.37 and a 1-year high of $34.08. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. The business’s fifty day moving average price is $26.04 and its two-hundred day moving average price is $21.73. The firm has a market capitalization of $2.95 billion, a PE ratio of -23.56 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.41. The company had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The company’s revenue for the quarter was up 1106.7% on a year-over-year basis. On average, research analysts expect that Liquidia Corporation will post -1.51 EPS for the current year.

Insider Activity

In other Liquidia news, CEO Roger Jeffs sold 20,261 shares of the company’s stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $23.41, for a total value of $474,310.01. Following the completion of the transaction, the chief executive officer owned 1,032,973 shares in the company, valued at approximately $24,181,897.93. This represents a 1.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Kaseta sold 11,630 shares of Liquidia stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $23.41, for a total value of $272,258.30. Following the sale, the chief financial officer directly owned 352,646 shares in the company, valued at approximately $8,255,442.86. This trade represents a 3.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 215,168 shares of company stock worth $5,675,425 over the last three months. Insiders own 26.50% of the company’s stock.

Analysts Set New Price Targets

LQDA has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a report on Wednesday, October 8th. HC Wainwright lifted their price objective on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Wells Fargo & Company started coverage on shares of Liquidia in a research note on Monday, October 20th. They set an “overweight” rating and a $31.00 target price for the company. Needham & Company LLC raised their price target on shares of Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $49.00 price target on shares of Liquidia in a report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.56.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).